Oropharyngeal Cancer Oropharyngeal Neoplasms
Conditions
Interventions
Male patients from age 18 years diagnosed with a first primary diagnosis of OPC under specific ICD-10 code during 2021-2025 and with an untreated oropharyngeal tissue sample available at the biobank o
Other
Male OPC Patients
Sponsors
MSD (Thailand) Ltd.
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male patients who aged 18 years old or older at OPC diagnosis 2. Patients who were diagnosed with first primary OPC which identified by specific list of cancer ICD-10 in the time-period from January 2021 to December 2025 3. Patients with an available untreated biopsy or resection tissue sample of oropharynx which obtained as part of regular clinical practice procedures for OPC diagnosis or clinical management 4. Patients who are willing to provide written informed consent, if required per site regulations 5. The tumor tissue specimen should be adequately preserved in formalin (preferably fixed in neutral, buffered-formalin) and embedded in paraffin 6. The paraffin blocks should be appropriate size to allow good fixation and permit re-cutting
Exclusion criteria
Exclusion criteria: 1. Patient whose tumor is classified as C14 (pharynx, unspecified), based on ICD-10 classification 2. Patients for whom only fine needle aspiration samples from metastatic lymph nodes are available 3. Patients with low quality tissue samples that do not allow an appropriate assessment of HPV test 4. Patients for whom histopathological examination on hematoxylin and eosin sections does not confirm the presence of invasive cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV-attributable fractions in OPC Single timepoint Proportion of OPC cases classified as HPV-attributable, defined by positivity for both HPV DNA testing and p16INK4a IHC | — |
Secondary
| Measure | Time frame |
|---|---|
| Distribution of HPV genotypes Single timepoint Proportion of each HPV genotype among HPV-attributable cases, determined using a validated HPV DNA genotyping assay,Characteristics of patients included in the study Single timepoint Collection of information from medical records | — |
Countries
Thailand
Contacts
Public ContactKanitta Watcharanurak
MSD (Thailand) Ltd.
Outcome results
None listed